Strides Pharma Science Intrinsic Value
Strides Pharma Science (STAR) median intrinsic value is ₹850.99 from 9 valuation models (range ₹353–₹1212), vs current price ₹1154.40 — -26.3% downside (Trading Above Calculated Value), margin of safety -35.7%. Browse STAR annual financials for revenue, profit, balance sheet and cash flow data.
STAR Valuation Methods Summary — DCF, Graham Number & P/E
Strides Pharma Science intrinsic value across 9 models vs current price ₹1154.40 — upside/downside and value range per method. For current market price and key ratios, visit Strides Pharma Science screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1211.76 | ₹969.41 - ₹1454.11 | +5.0% | EPS: ₹55.08, Sector P/E: 22x |
| Book Value Method | asset | ₹675.65 | ₹608.09 - ₹743.22 | -41.5% | Book Value/Share: ₹337.83, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1159.13 | ₹1043.22 - ₹1275.04 | +0.4% | Revenue/Share: ₹579.57, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1056.52 | ₹950.87 - ₹1162.17 | -8.5% | EBITDA: ₹972.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹918.30 | ₹734.64 - ₹1101.96 | -20.5% | CF Growth: 12.5%, Discount: 15% |
| PEG Ratio Method | growth | ₹352.51 | ₹317.26 - ₹387.76 | -69.5% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹850.99 | ₹765.89 - ₹936.09 | -26.3% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹785.22 | ₹706.70 - ₹863.74 | -32.0% | ROE: 16.6%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹647.05 | ₹582.35 - ₹711.75 | -43.9% | EPS: ₹55.08, BVPS: ₹337.83 |
STAR Intrinsic Value vs Market Price — All Valuation Models
Strides Pharma Science fair value range ₹353–₹1212 vs current market price ₹1154.40 across 9 valuation models. Also explore STAR share price data to track price trends across different timeframes.
STAR Intrinsic Value Analysis — Undervalued or Overvalued?
Strides Pharma Science median intrinsic value ₹850.99, current price ₹1154.40 — Trading Above Calculated Value by 26.3%, margin of safety -35.7%.
What is the intrinsic value of STAR?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Strides Pharma Science (STAR) is ₹850.99 (median value). With the current market price of ₹1154.40, this represents a -26.3% variance from our estimated fair value.
The valuation range spans from ₹352.51 to ₹1211.76, indicating ₹352.51 - ₹1211.76.
Is STAR undervalued or overvalued?
Based on our multi-method analysis, Strides Pharma Science (STAR) appears to be trading above calculated value by approximately 26.3%.
STAR Financial Health — Key Ratios vs Industry Benchmarks
Strides Pharma Science financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 4.10 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 16.6% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 18.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.77x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
STAR Cash Flow Quality — Operating & Free Cash Flow
Strides Pharma Science operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹684 Cr | ₹639 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹701 Cr | ₹626 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹44 Cr | ₹44 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹-258 Cr | ₹-318 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹481 Cr | ₹220 Cr | Positive Free Cash Flow | 7/10 |